MAMA:NASDAQMama's Creations, Inc. Analysis
Data as of 2026-04-16 - not real-time
$15.70
Latest Price
7/10Risk
Risk Level: Medium
Executive Summary
Mama's Creations, Inc. (MAMA) is trading around $15.70, well above its discounted cash‑flow fair value of roughly $2.68, implying a substantial premium. The stock carries an eye‑popping trailing P/E of ~120× and a P/B of ~13×, while revenue has surged 60.7% year‑over‑year, suggesting strong top‑line momentum but still modest profitability (operating margin ~3.4%).
Technical signals are mixed but mildly optimistic: the 20‑day SMA (15.27) sits just below the current price, the MACD histogram is positive and the RSI is neutral at 52, with support near $14.05 and resistance around $16.49. Volume is on an upward trend, and the market sentiment is in “Extreme Greed” territory (Fear & Greed Index 88.98). Recent analyst upgrades to a Zacks Rank 1 “Strong Buy” and an expected Q4 EPS of $0.04 add short‑term upside, yet the valuation gap and high volatility (≈45% 30‑day) temper enthusiasm for a long‑run hold.
Technical signals are mixed but mildly optimistic: the 20‑day SMA (15.27) sits just below the current price, the MACD histogram is positive and the RSI is neutral at 52, with support near $14.05 and resistance around $16.49. Volume is on an upward trend, and the market sentiment is in “Extreme Greed” territory (Fear & Greed Index 88.98). Recent analyst upgrades to a Zacks Rank 1 “Strong Buy” and an expected Q4 EPS of $0.04 add short‑term upside, yet the valuation gap and high volatility (≈45% 30‑day) temper enthusiasm for a long‑run hold.
Market Outlook
Short Term
< 1 yearPositive
Model confidence: 7/10
Key Factors
- Upcoming earnings beat expectations
- Technical bullish MACD histogram and price above 20‑day SMA
- Analyst upgrade to Strong Buy
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- Rapid revenue growth but thin margins
- Continued overvaluation relative to DCF
- Increasing trading volume supporting liquidity
Long Term
> 3 yearsCautious
Model confidence: 4/10
Key Factors
- Extreme valuation premium (P/E >120×, P/B >12×)
- High price volatility and beta below 1
- Lack of dividend and modest cash‑flow generation
Key Metrics & Analysis
Financial Health
Revenue Growth60.70%
Profit Margin3.08%
P/E Ratio120.8
ROE13.64%
ROA6.70%
Debt/Equity27.49
P/B Ratio12.9
Op. Cash Flow$11.4M
Free Cash Flow$2.8M
Technical Analysis
TrendNeutral
RSI52.3
Support$14.05
Resistance$16.49
MA 20$15.27
MA 50$15.74
MA 200$12.03
MACDBullish
VolumeIncreasing
Fear & Greed Index88.98
Valuation
Fair Value$2.68
Target Price$22.00
Upside/Downside40.13%
GradeOvervalued
TypeGrowth
Risk Assessment
Beta0.78
Volatility44.95%
Sector RiskLow
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.